Evidence map›Paper›PMID 41194592›Full record

ArticleBJOG : an international journal of obstetrics and gynaecology2026

A Cost Consequence Analysis of Seven Diagnostic Strategies for Ovarian Cancer: A Model-Based Economic Evaluation.

Samuel J Perry, Donal Griffin, Eleanor V Williams, Tracy E Roberts, Fong Lien Kwong, Sarah Williams, Jon Deeks, Katie Scandrett, Ridhi Agarwal, Sudha S Sundar and 1 more

Abstract read
In one paragraph

Article in BJOG : an international journal of obstetrics and gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Samuel J PerryDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Donal GriffinDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0009-0000-7974-7155
Eleanor V WilliamsDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Tracy E RobertsDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Fong Lien KwongDepartment of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0002-6245-2358
Sarah WilliamsUniversity Hospitals Birmingham, Birmingham, UK.
Jon DeeksDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Katie ScandrettDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Ridhi AgarwalDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Sudha S SundarDepartment of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0002-5843-3015
Mark MonahanDepartment of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.

Funding

National Institute for Health and Care Research
6 · The paper itself

Abstract

objectiveTo assess the costs and consequences of seven diagnostic strategies for ovarian cancer in pre- and post-menopausal women with symptoms in secondary care.

designEconomic evaluation alongside a prospective single-arm diagnostic accuracy study.

settingNHS secondary care outpatients (2-week referrals, clinics, GP referrals, cross-specialty referrals) and inpatients (emergency presentations to secondary care). SAMPLE: Two cohorts of 857 pre-menopausal and 1242 post-menopausal women newly presenting to secondary care with symptoms of suspected ovarian cancer.

methodsA model-based cost-consequence analysis (CCA) was conducted using a decision tree simulating patient pathways over 12 months. Diagnostic accuracy data were sourced from the ROCkeTS study and supplemented by literature.

main outcome measuresCancer deaths, correct diagnosis proportion, and diagnostic yield.

resultsNo diagnostic strategy was optimal across all outcomes. Across both cohorts, the Risk of Malignancy Index (RMI) 200 was least expensive but had poor cancer death and diagnostic yield outcomes. The ADNEX 3% strategy had the highest diagnostic yield and lowest cancer mortality but was the most expensive. For pre-menopausal women, the IOTA ADNEX 10% strategy outperformed ORADS, ROMA, and CA125 in cost and outcomes. For post-menopausal women, the high cancer prevalence required a trade-off. In sensitivity analysis, a two-step IOTA ADNEX 10% strategy outperformed ORADS, ROMA, and CA125 across all three outcomes, making the strategy a more balanced choice in both cohorts.

conclusionAt 12 months, no single diagnostic strategy was superior. Early diagnosis requires balancing cancer mortality, diagnostic yield, and cost. The IOTA ADNEX two-step strategy at a 10% threshold provided the best trade-off across these factors and is recommended for practice.

Indexed as

Early Detection of CancerOvarian NeoplasmsAdultAgedCA-125 AntigenCost-Benefit AnalysisFemaleHumansMiddle AgedModels, EconomicPostmenopausePremenopauseProspective StudiesReferral and ConsultationSecondary Health CareUnited KingdomCA-125 Antigencost‐effectivenesseconomic evaluationgynaecologic cancermenopauseultrasound

Identifiers

PMID41194592
PMCPMC12884228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.